Loughborough, England, Aug. 09, 2019 (GLOBE NEWSWIRE) -- – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today reported financial results for the first quarter ended June 30, 2019.
13 julio, 2019
29 enero, 2019
Amazon Prime Day Camera Deals 2019: The Best DJI, GoPro, Canon & Nikon DSLR, Arlo & Nest Security Camera Sales Compared by Save Bubble
Hace 4 semanas